What this test measures
Lp-PLA2 (also called platelet-activating factor acetylhydrolase, PAF-AH) is an enzyme produced by inflammatory cells (macrophages, T cells) and carried on LDL particles in plasma. It hydrolyses oxidised LDL phospholipids, generating pro-inflammatory mediators that promote plaque instability. Unlike CRP (general inflammation), Lp-PLA2 is relatively specific to vascular wall inflammation — making it a candidate marker for refined CV risk assessment in borderline-risk individuals.
Why it matters
Indian guideline endorsement is modest. Lp-PLA2 has the strongest evidence in patients whose 10-year ASCVD risk is intermediate (5–20%) and the clinician is deciding whether to start a statin. A high Lp-PLA2 supports statin initiation; a low value supports lifestyle measures alone. Not useful in patients already on statins (statins lower Lp-PLA2 substantially), in established CVD (statin already indicated), or in low-risk populations (false positives outnumber true positives).
How to prepare
Fast 8–12 hours preferred. Stop statins / fibrates 2 weeks before only if specifically advised — usually not necessary. Disclose recent infection, surgery, or autoimmune flare (transiently raise Lp-PLA2).
Markers & reference ranges
Reference ranges below are typical adult values. Your lab's reported range may differ slightly based on the assay platform and patient demographics — always read your report against the range printed on it.
| Marker | Normal range | If low | If high |
|---|---|---|---|
| Lp-PLA2 (ng/mL)[1][2] | Adults < 200 | Lower values associated with lower CV event risk. | > 200 ng/mL: associated with ~2-fold higher CV event risk independent of traditional risk factors. > 235 supports statin initiation in intermediate-risk patients. Falsely raised by inflammation (recent infection, surgery, autoimmune flare). |
Lp-PLA2 bands and CV risk implication
| Lp-PLA2 (ng/mL) | Risk band | Action |
|---|---|---|
| < 150 | Low | Continue lifestyle measures |
| 150 – 200 | Average | Risk-factor based decision |
| 200 – 235 | Elevated | Consider lifestyle intensification, statin if other risk factors |
| > 235 | High | Supports statin initiation in intermediate risk |
Frequently asked questions
Is this a screening test?
No — Lp-PLA2 is a refinement marker for intermediate-risk individuals where the statin decision is borderline. Mass screening is not endorsed by AHA, ESC or ACC.
Why not just use CRP?
CRP measures generalised inflammation — rising in any infection or inflammatory state. Lp-PLA2 is more vascular-specific. They are complementary, not redundant.
Will statins affect the result?
Yes — statins lower Lp-PLA2 by 20–30%. Patients already on statins do not benefit from testing.
Is this useful in diabetes?
Modestly — in T2DM with intermediate ASCVD risk, Lp-PLA2 may refine decisions. Most diabetics already qualify for statin therapy and don't need the test.
How often should I repeat?
Not routinely. A single value at the time of CV risk assessment is sufficient. Trend-tracking is not validated.
Related Cardiac Markers tests
Tests commonly ordered alongside LP-PLA2, or that help interpret an unexpected result.
Sources & references
- AHA Scientific Statement — Lp-PLA2 · accessed 2026-05-30T00:00:00.000Z
- NIH MedlinePlus — Cardiac Risk Markers · accessed 2026-05-30T00:00:00.000Z
- Mayo Clinic Labs — Lp-PLA2 · accessed 2026-05-30T00:00:00.000Z
Book with Zelnoo
Get your LP-PLA2 test done at home — transparent prices, NABL-accredited labs.
Zelnoo lets you compare diagnostic test prices across NABL-accredited labs in Mumbai & Thane, book a free home phlebotomist visit, and receive digital reports in 24–48 hours into a consent-first report vault. No subscriptions, no membership fees — pay only for the test you book.
Book LP-PLA2 now